DNA methylation in prostate cancer.

Prostate cancer is the most common malignancy and the second leading cause of cancer death among men in the United States. There are three well-established risk factors for prostate cancer: age, race and family history. The molecular bases for these risk factors are unclear; however, they may be influenced by epigenetic events. Epigenetic events covalently modify chromatin and alter gene expression. Methylation of cytosine residues within CpG islands on gene promoters is a primary epigenetic event that acts to suppress gene expression. In tumorigenesis, the normal functioning of the epigenetic-regulatory system is disrupted leading to inappropriate CpG island hypermethylation and aberrant expression of a battery of genes involved in critical cellular processes. Cancer-dependent epigenetic regulation of genes involved in DNA damage repair, hormone response, cell cycle control and tumor-cell adhesion/metastasis can contribute significantly to tumor initiation, progression and metastasis and, thereby, increase prostate cancer susceptibility and risk. In this review, we will discuss current research on genes that are hypermethylated in human prostate cancer. We will also discuss the potential involvement of DNA methylation in age-related, race-related and hereditary prostate cancer, and the potential use of hypermethylated genes as biomarkers to detect prostate cancer and assess its risk.

[1]  Tudung T Nguyen,et al.  Analysis of cyclin‐dependent kinase inhibitor expression and methylation patterns in human prostate cancers , 2000, The Prostate.

[2]  J. Köllermann,et al.  Methylation-Specific PCR for DNA-Based Detection of Occult Tumor Cells in Lymph Nodes of Prostate Cancer Patients , 2003 .

[3]  J. Mann,et al.  Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma , 2004, Oncogene.

[4]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[5]  J. Herman,et al.  Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.

[6]  H. Klocker,et al.  Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides , 2000, Cancer Gene Therapy.

[7]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.

[8]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[9]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  A. Protopopov,et al.  The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. , 2002, Cancer research.

[11]  R. Singal,et al.  Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. , 2001, Cancer research.

[12]  M. Becich,et al.  Methylation of the CD44 metastasis suppressor gene in human prostate cancer. , 1999, Cancer research.

[13]  Hong Zhao,et al.  PGDB: a curated and integrated database of genes related to the prostate , 2003, Nucleic Acids Res..

[14]  M. Toyota,et al.  Epigenetic Regulation of the KAI1 Metastasis Suppressor Gene in Human Prostate Cancer Cell Lines , 2001, Japanese journal of cancer research : Gann.

[15]  A. Nagafuchi,et al.  Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. , 1997, Cancer research.

[16]  R. Dahiya,et al.  Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. , 2002, Journal of the National Cancer Institute.

[17]  N. Tanji,et al.  Immunohistochemical study of the receptors for retinoic acid in prostatic adenocarcinoma. , 2000, Anticancer research.

[18]  M. Banerjee,et al.  Should African‐American men be tested for prostate carcinoma at an earlier age than white men? , 1999, Cancer.

[19]  M. Esteller.  Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. , 2000, European journal of cancer.

[20]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[21]  H. Ostrer,et al.  Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma , 2003, Cancer.

[22]  J. Issa,et al.  Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. , 1999, Cardiovascular research.

[23]  S. Baylin,et al.  Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. , 1996, Cancer research.

[24]  T. H. van der Kwast,et al.  Feasibility of assessment of promoter methylation of the CD44 gene in serum of prostate cancer patients. , 2001, Molecular urology.

[25]  F. Bazzoli,et al.  Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. , 2003, Cancer research.

[26]  C. Walsh,et al.  Cytosine methylation and the ecology of intragenomic parasites. , 1997, Trends in genetics : TIG.

[27]  N. Konishi,et al.  Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy. , 1993, Oncology.

[28]  C. Huggins.  Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. , 1965, Cancer research.

[29]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[30]  R. Burk,et al.  Role of family history and ethnicity on the mode and age of prostate cancer presentation * , 2002, The Prostate.

[31]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia , 2004, The Journal of pathology.

[32]  S. Hirohashi,et al.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. H. van der Kwast,et al.  The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  N. Verkaik,et al.  Silencing of CD44 Expression in Prostate Cancer by Hypermethylation of the CD44 Promoter Region , 2000, Laboratory Investigation.

[35]  N. Olea,et al.  Negative controls of cell proliferation: human prostate cancer cells and androgens. , 1989, Cancer research.

[36]  J. Tangrea,et al.  A survey of gene-specific methylation in human prostate cancer among black and white men. , 2004, Cancer letters.

[37]  H. Klocker,et al.  Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors , 1997, The Journal of pathology.

[38]  A. D. De Marzo,et al.  GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer , 2004, Journal of cellular biochemistry.

[39]  W. Isaacs,et al.  Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. , 2001, Cancer research.

[40]  I. Leav,et al.  Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .

[41]  K. Miller,et al.  Methylation‐specific PCR for detection of neoplastic DNA in biopsy washings , 2002, The Journal of pathology.

[42]  R. Dahiya,et al.  Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. , 2000, Cancer research.

[43]  J. Lehmann,et al.  Cloning and Characterization of Human Estrogen Receptor β Isoforms , 1998 .

[44]  K. Korach,et al.  Prostate phenotypes in estrogen-modulated transgenic mice , 2002, Trends in Endocrinology & Metabolism.

[45]  Jeanne Kowalski,et al.  Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer , 2004, Cancer Research.

[46]  A. Bird.  CpG-rich islands and the function of DNA methylation , 1986, Nature.

[47]  S. Hirohashi,et al.  The E‐cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas , 1997, International journal of cancer.

[48]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[49]  A. Okamoto,et al.  p16INK4 mutations and altered expression in human tumors and cell lines. , 1994, Cold Spring Harbor symposia on quantitative biology.

[50]  R. Hayes,et al.  Hypermethylation of GSTP1, CD44, and E‐cadherin genes in prostate cancer among US Blacks and Whites , 2003, The Prostate.

[51]  G. Carruba,et al.  Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. , 1994, Cancer research.

[52]  B. Harfe,et al.  DNA mismatch repair and genetic instability. , 2000, Annual review of genetics.

[53]  M. Toyota,et al.  CpG island methylator phenotypes in aging and cancer. , 1999, Seminars in cancer biology.

[54]  G. Carruba,et al.  Human prostate cancer: a direct role for oestrogens. , 1995, Ciba Foundation symposium.

[55]  W. Nelson,et al.  Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  M. Toyota,et al.  Epigenetic Regulation of Androgen Receptor Gene Expression in Human Prostate Cancers , 2000, Laboratory Investigation.

[57]  V. Speights,et al.  Hypermethylation of the caveolin‐1 gene promoter in prostate cancer , 2001, The Prostate.

[58]  M. Frommer,et al.  CpG islands in vertebrate genomes. , 1987, Journal of molecular biology.

[59]  M. Thun,et al.  Family History and Risk of Fatal Prostate Cancer , 1997, Epidemiology.

[60]  E. Winn-Deen,et al.  Decreased expression of catenins (α and β), p120 CTN, and E‐cadherin cell adhesion proteins and E‐cadherin gene promoter methylation in prostatic adenocarcinomas , 2001 .

[61]  S. Baylin,et al.  Aging and DNA methylation in colorectal mucosa and cancer. , 1998, Cancer research.

[62]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[63]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[64]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[65]  D. Bostwick,et al.  Prostatic Intra‐Epithelial Neoplasia and Early Invasion in Prostate Cancer , 1987, Cancer.

[66]  P. Rennie,et al.  Epigenetic Mechanisms for Progression of Prostate Cancer , 1998, Cancer and Metastasis Reviews.

[67]  Daniel J Schaid,et al.  The complex genetic epidemiology of prostate cancer. , 2004, Human molecular genetics.

[68]  L. M. Luca,et al.  Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. , 1991 .

[69]  W. Hop,et al.  Reduced expression of the cadherin–catenin complex in oesophageal adenocarcinoma correlates with poor prognosis , 1997, The Journal of pathology.

[70]  T. H. van der Kwast,et al.  Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective , 2001, BJU international.

[71]  C. Swanton.  Cell-cycle targeted therapies. , 2004, The Lancet. Oncology.

[72]  R. Lotan,et al.  Differential expression of nuclear retinoid receptors in normal and malignant prostates. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  W. Schulz,et al.  High frequency of alterations in DNA methylation in adenocarcinoma of the prostate , 1999, The Prostate.

[74]  L. Kasturi,et al.  Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[75]  M. Loriot,et al.  Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer , 2004, International journal of cancer.

[76]  B. Mannervik,et al.  Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. Herman,et al.  Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. , 1998, Cancer research.

[78]  John Calvin Reed,et al.  Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells , 1996, Molecular and cellular biology.

[79]  J. Minna,et al.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. , 2001, Cancer research.

[80]  Keith R. Johnson,et al.  Cadherin-mediated cellular signaling. , 2003, Current opinion in cell biology.

[81]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[82]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[83]  M. Schofield,et al.  DNA mismatch repair: molecular mechanisms and biological function. , 2003, Annual review of microbiology.

[84]  F. Hirsch,et al.  The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. , 2002, Lung cancer.

[85]  A. Gazdar,et al.  Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  John D Minna,et al.  Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  Tsung-Teh Wu,et al.  Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  K. Miller,et al.  Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. , 2000, Cancer research.

[89]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[90]  W F Bodmer,et al.  The ABC of APC. , 2001, Human molecular genetics.

[91]  G. Pfeifer,et al.  Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas , 2001, International journal of cancer.

[92]  I. Näthke,et al.  The adenomatous polyposis coli protein. , 1999, Molecular pathology : MP.

[93]  A. Bell,et al.  Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis* , 2000, The Journal of Biological Chemistry.

[94]  D. V. Von Hoff,et al.  5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells. , 1999, Anticancer research.

[95]  Qifeng Yang,et al.  Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer. , 2001, The American journal of pathology.

[96]  K. Akakura,et al.  Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer , 2001, The Prostate.

[97]  Y. Chen,et al.  Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. , 2001, Carcinogenesis.

[98]  Satoru Takahashi,et al.  DNA methylation in the androgen receptor gene promoter region in rat prostate cancers , 2002, The Prostate.

[99]  J. Herman,et al.  E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[100]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[101]  T. DeWeese,et al.  The Diet, Prostate Inflammation, and the Development of Prostate Cancer , 2004, Cancer and Metastasis Reviews.

[102]  G. Pfeifer,et al.  Frequent hypermethylation of the RASSF1A gene in prostate cancer , 2002, Oncogene.

[103]  S. Weitzman,et al.  Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[104]  L. Skoog,et al.  Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue , 1992, The Prostate.

[105]  S. Hirohashi.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. , 1998, The American journal of pathology.

[106]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[107]  W. Isaacs,et al.  Human prostate cancer precursors and pathobiology. , 2003, Urology.

[108]  P. Tam,et al.  Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia1 , 2004, Clinical Cancer Research.

[109]  T. Huang,et al.  Methylation profiling of CpG islands in human breast cancer cells. , 1999, Human molecular genetics.

[110]  J. Carpten,et al.  African-American heredity prostate cancer study: a model for genetic research. , 2001, Journal of the National Medical Association.

[111]  J. Brooks,et al.  CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[112]  A. Mes-Masson,et al.  Analysis of the p16 tumor suppressor gene in early‐stage prostate cancer , 1998, Molecular carcinogenesis.

[113]  J. Minna,et al.  Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  S. Groshen,et al.  Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[115]  N. Ahuja,et al.  Aging, methylation and cancer. , 2000, Histology and histopathology.

[116]  Masatoshi Watanabe,et al.  The Role of Epigenetic Modifications in Retinoic Acid Receptor β2 Gene Expression in Human Prostate Cancers , 2001, Laboratory Investigation.

[117]  S. Ho,et al.  PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model , 2004, Oncogene.

[118]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[119]  A. Rustgi,et al.  DNA mismatch repair and cancer. , 1995, Gastroenterology.

[120]  J. Isaacs,et al.  CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. , 1997, Cancer research.

[121]  K. Miller,et al.  DNA-based detection of prostate cancer in urine after prostatic massage. , 2001, Urology.

[122]  S. Groshen,et al.  Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. , 1998, Journal of the National Cancer Institute.

[123]  G. Berx,et al.  The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression , 2001, Breast Cancer Research.

[124]  J. Herman,et al.  Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. , 2001, Cancer research.

[125]  T. H. van der Kwast,et al.  Down‐regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation , 1999, International journal of cancer.

[126]  J. Herman,et al.  Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer , 1997, Genes, chromosomes & cancer.

[127]  J. Gustafsson,et al.  Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer , 2001 .

[128]  A. Petrenko,et al.  Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer , 2002, BMC Cancer.

[129]  S. Baylin,et al.  Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon , 1994, Nature Genetics.

[130]  R A Stephenson,et al.  Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. , 2001, Journal of the National Cancer Institute.

[131]  D. Sidransky,et al.  I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[132]  L. Liotta,et al.  Tumor cell interactions with the extracellular matrix during invasion and metastasis. , 1993, Annual review of cell biology.

[133]  Su Jeong Song,et al.  The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex , 2004, Nature Cell Biology.

[134]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[135]  B. Dynlacht,et al.  Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition , 1995, Nature.

[136]  J. Epstein,et al.  Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. , 2003, The Journal of urology.

[137]  V. Kosma,et al.  Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer , 1999, The Prostate.

[138]  C. Amos,et al.  Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. , 2003, Cancer research.

[139]  S. Ho,et al.  Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. , 2000, Cancer research.

[140]  Mitsutoshi Nakamura,et al.  DNA Hypermethylation Status of Multiple Genes in Prostate Adenocarcinomas , 2002, Japanese journal of cancer research : Gann.

[141]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[142]  V. Rossi,et al.  Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. , 2001, The Journal of clinical endocrinology and metabolism.

[143]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[144]  E. Campo,et al.  Cell cycle regulators and their abnormalities in breast cancer. , 1998, Molecular pathology : MP.

[145]  A. Friedl,et al.  Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. , 2000, Cancer research.

[146]  J. Trachtenberg,et al.  Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor , 1997, Molecular and Cellular Endocrinology.

[147]  R. Eeles,et al.  Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. , 2001, Pharmacogenetics.

[148]  G. Pfeifer,et al.  Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene , 2004, Oncogene.

[149]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[150]  J. Hicks,et al.  Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. , 2003, The American journal of pathology.

[151]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[152]  Hiroyuki Takahashi,et al.  Altered methylation of multiple genes in carcinogenesis of the prostate , 2003, International journal of cancer.

[153]  A. Neugut,et al.  The "skinny" on obesity and prostate cancer prognosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  P. Carroll,et al.  Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. , 2001, The Journal of urology.

[155]  Jun Zhao,et al.  Growth inhibiting effects of antisense eukaryotic expression vector of proliferating cell nuclear antigen gene on human bladder cancer cells. , 2003, Chinese medical journal.

[156]  M. Frydenberg,et al.  Hypermethylation of the Inhibin α-Subunit Gene in Prostate Carcinoma , 2002 .

[157]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[158]  J. Eyfjord,et al.  GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[159]  S. Toyooka,et al.  Epigenetic Regulation of a Novel Tumor Suppressor Gene (hDAB2IP) in Prostate Cancer Cell Lines* 210 , 2003, The Journal of Biological Chemistry.

[160]  R. Uzzo,et al.  Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. , 2003, Cancer research.

[161]  E. Crawford,et al.  Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. , 2000, Molecular and cellular probes.

[162]  H. Moch,et al.  Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. , 2001, Cancer research.

[163]  B. Horsthemke,et al.  Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma , 1994, Human Genetics.

[164]  R. Dahiya,et al.  CpG hypermethylation of the promoter region inactivates the estrogen receptor‐β gene in patients with prostate carcinoma , 2001, Cancer.

[165]  P. Campos,et al.  Endothelin B receptor gene hypermethylation in prostate adenocarcinoma , 2003, Journal of clinical pathology.

[166]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. , 2001, Cancer research.

[167]  G. Folkers,et al.  Genomic organization of the human retinoic acid receptor β2 , 1992 .

[168]  C. Eng,et al.  RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours , 2001, Oncogene.

[169]  W. Isaacs,et al.  CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[170]  M. Takeichi,et al.  Cadherin cell adhesion receptors as a morphogenetic regulator. , 1991, Science.

[171]  K. Uzawa,et al.  Reduced expression of E-cadherin in oral squamous cell carcinoma: relationship with DNA methylation of 5' CpG island. , 1998, International journal of oncology.

[172]  K. Robertson.  DNA methylation and chromatin – unraveling the tangled web , 2002, Oncogene.

[173]  F. Kaye,et al.  Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. , 1994, Oncogene.